| P/E (FY) | — | Sales (TTM) | $8.4M |
| Earnings (TTM) | -$237.4M | ROE | −86.68% |
| Net Margin | −1011.75% | ROIC | −237.26% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing medicines for autoimmune disorders. Its candidates include envudeucitinib, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus, and A-005, a CNS-penetrant allosteric TYK2 inhibitor in Phase 1 for neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, an IGF-1R monoclonal antibody for thyroid eye disease, and an IRF5 program for immune dysfunction.
| Market Cap | $2.30B | Trading Days | 518 |
| 52W High | 31.35 |
| 52W Low | 3.75 |
| % Off High | −13.78% |
| YTD | 176.95% | 1Y | 569.06% |
| Since incept. (ann.) | 40.61% |
Single Reportable 100%
| Ann. Volatility (1Y) | 121.58% | Ann. Volatility (3Y) | 114.60% |
| Sharpe (1Y) | 2.05 | Sharpe (3Y) | 0.79 |
| Max Drawdown (1Y) | −36.66% | Max Drawdown (3Y) | −78.95% |
| Beta (3Y, vs SPY) | −0.60 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $2.33B | — |
| KLRA | Kailera Therapeutics, Inc. | $2.26B | — |
| MLYS | Mineralys Therapeutics, Inc. | $2.22B | — |
| NKTR | NEKTAR THERAPEUTICS | $2.39B | — |
| VERA | Vera Therapeutics, Inc. | $2.39B | — |
| AMLX | Amylyx Pharmaceuticals, Inc. | $2.17B | — |
| PBH | Prestige Consumer Healthcare Inc. | $2.45B | 13.2 |
| AGIO | AGIOS PHARMACEUTICALS, INC. | $2.14B | — |
| NRIX | Nurix Therapeutics, Inc. | $2.51B | — |
| SION | Sionna Therapeutics, Inc. | $2.10B | — |
| IMUX | IMMUNIC, INC. |
| $2.08B |
| — |
| BHVN | Biohaven Ltd. | $2.07B | — |
